WO2011063597A1 - Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation - Google Patents

Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2011063597A1
WO2011063597A1 PCT/CN2010/001769 CN2010001769W WO2011063597A1 WO 2011063597 A1 WO2011063597 A1 WO 2011063597A1 CN 2010001769 W CN2010001769 W CN 2010001769W WO 2011063597 A1 WO2011063597 A1 WO 2011063597A1
Authority
WO
WIPO (PCT)
Prior art keywords
culture
bacteria
yeast
bacillus
microbial preparation
Prior art date
Application number
PCT/CN2010/001769
Other languages
English (en)
Chinese (zh)
Inventor
王立平
Original Assignee
Wang Liping
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wang Liping filed Critical Wang Liping
Priority to JP2012540257A priority Critical patent/JP5525622B2/ja
Priority to US13/257,368 priority patent/US20120093779A1/en
Priority to EP10832504.4A priority patent/EP2386624B1/fr
Publication of WO2011063597A1 publication Critical patent/WO2011063597A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Definitions

  • the composite microbial preparation main body of the invention It is composed of a variety of probiotic components, including photosynthetic bacteria, Bacillus, yeast, lactobacilli and actinomycetes.
  • the proportion of the components by volume is 5 ⁇ 15% of photosynthetic bacteria, 10-20% of Bacillus, 20 ⁇ 35% of yeast, 30 ⁇ 45% of lactobacillus, and 3 ⁇ 10% of actinomycetes;
  • the volume ratio is 5-10% for photosynthetic bacteria, 10-14% for Bacillus, 30-35% for yeast, 41-45% for lactobacilli, and 3 ⁇ 8% for actinomycetes; more preferably,
  • the volume ratio is 10% for photosynthetic bacteria, 10% for Bacillus, 30% for yeast, 45% for lactobacilli, and 5% for actinomycetes;
  • Another object of the present invention is to provide a process for the preparation of such a composite microbial preparation.
  • the preparation method comprises the steps of subjecting photosynthetic bacteria, Bacillus, yeast, Lactobacillus and actinomycetes to one-stage composite fermentation and two-stage composite fermentation.
  • Sampling and testing of the second-composite bacterial liquid The appearance is liquid, the color is the same, and the special odor is generated by microbial fermentation.
  • the pH value is directly measured by the acidity meter, and the normal value is between 5 and 8, and the live bacteria are measured by the plate counting method.
  • the number and number of bacteria, the total number of viable bacteria is greater than 5xl0 8 cfo / g, the bacteria rate ⁇ 5% is a good product.
  • the primary medium of Lactobacillus acidophilus is: KN0 3 lg, soluble starch 10 g, K 2 HPO 4 0.5 g, MgS0 4 0.5 g, NaCl 0.5 g, FeS0 4 0.01 g, agar 20 g, adjusted to volume with distilled water until 1000ml, pH7.2; Secondary medium: KNO 3 0.8 g, soluble starch 8 g, glucose 5 g, yeast juice 5 g, K 2 HPO 4 0.3 g, MgS0 4 0.2 g, NaCl 0.4 g, FeS0 4 0.05 g, make up to 1000ml with distilled water, ⁇ 7 ⁇ 2.
  • the culture pH is 7
  • the culture temperature is 32 ° C
  • the culture time is 3 days.
  • the fermentation bacterium of Lactobacillus acidophilus; after testing, the viable cell number of the bacteria in the fermentation broth is 20 ⁇ 10 8 30 30 10 8 .
  • 60L of the first-class strain of Streptomyces faecalis was inoculated into 600L of the secondary medium of the strain, aerated culture, the culture pH was 7, the culture temperature was 30 ° C, and the culture time was 6 days, and Streptomyces faecalis was obtained.
  • the fermentation broth; after testing, the number of viable bacteria of the bacteria in the fermentation broth is 30 ⁇ 10 8 ⁇ 50 ⁇ 10 8 .
  • the fermentation broth of each component is 5% according to Rhodopseudomonas palustris, 14% Bacillus subtilis, beer The volume ratio of wine yeast 32%, Lactobacillus acidophilus 41%, and 8% of Streptomyces faecalis was mixed in a 1000 L liquid storage tank to obtain a 1000 L-class composite bacteria.
  • the total number of viable bacteria in the obtained composite bacteria was 20 ⁇ 10 8 ⁇ 30 ⁇ 10 8 .
  • Rhodopseudomonas pallidum was 6%
  • Bacillus subtilis was 15°/. 33% for brewer's yeast, 42% for Lactobacillus acidophilus, and 4% for Streptomyces faecalis.
  • the composite microbial preparation according to the embodiment 1 of the present invention is used three times a day, orally for 10 minutes after a meal, 20 ml each time. 15 days is a course of treatment, taking six courses.
  • Precautions 1) Shake the bottom of the bottle upwards before taking it; 2) Do not drink water within 1 hour after taking it; 3) Do not control the diet; 4) Patients who use insulin can gradually reduce the amount of insulin within 7 days. Can be deactivated; 5) Other diabetes drugs can be gradually reduced within 15 days, and can be stopped after normal blood sugar; 6) Protected from light at room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une préparation microbienne complexe comprenant (en % en volume) : une bactérie photosynthétique (5-15 %), un bacille (10-20 %), des levures (20-35 %), un lactobacille (30-45 %) et des actinomycètes (3-10 %). Le procédé de préparation de la préparation microbienne complexe comprend des fermentations complexes de premier et second niveaux. La fermentation complexe de premier niveau consiste à : (a) inoculer séparément les bactéries susmentionnées sur un milieu de culture de premier niveau et effectuer la culture pour obtenir des bactéries de premier niveau, (b) inoculer séparément les bactéries de premier niveau obtenues sur un milieu de culture de second niveau et effectuer la culture pour obtenir des liquides bactériens fermentés, (c) mélanger les cinq liquides bactériens fermentés obtenus pour obtenir des bactéries mélangées de premier niveau. La fermentation complexe de second niveau consiste à : ajouter de l'eau stérilisée, Lactobacillus plantarum, Saccharomyces cerevisiae et du sucre roux aux bactéries mélangées de premier niveau obtenues, mélanger uniformément dans un même fermenteur et effectuer la culture pour obtenir une préparation microbienne complexe de second niveau. La préparation microbienne complexe est utilisée dans le traitement pour le diabète.
PCT/CN2010/001769 2009-11-25 2010-11-03 Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation WO2011063597A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012540257A JP5525622B2 (ja) 2009-11-25 2010-11-03 糖尿病治療用複合微生物製剤及びその製造方法と利用
US13/257,368 US20120093779A1 (en) 2009-11-25 2010-11-03 Complex microbial preparation for treating diabetes and preparative method and use thereof
EP10832504.4A EP2386624B1 (fr) 2009-11-25 2010-11-03 Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910238778.5 2009-11-25
CN2009102387785A CN101703528B (zh) 2009-11-25 2009-11-25 一种治疗糖尿病的复合微生物制剂及其制备方法和应用

Publications (1)

Publication Number Publication Date
WO2011063597A1 true WO2011063597A1 (fr) 2011-06-03

Family

ID=42373825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2010/001769 WO2011063597A1 (fr) 2009-11-25 2010-11-03 Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation

Country Status (5)

Country Link
US (1) US20120093779A1 (fr)
EP (1) EP2386624B1 (fr)
JP (1) JP5525622B2 (fr)
CN (1) CN101703528B (fr)
WO (1) WO2011063597A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013133312A (ja) * 2011-12-27 2013-07-08 Tropical Plant Resources Institute Inc 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
CN112772351A (zh) * 2021-01-15 2021-05-11 东北农业大学 一种马铃薯脱毒苗栽培基质及其制备方法
CN114276955A (zh) * 2021-12-15 2022-04-05 天津科技大学 一种固态发酵马铃薯薯渣生产蛋白饲料的微生物菌剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101703528B (zh) * 2009-11-25 2012-07-04 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用
CN104524024B (zh) * 2014-12-15 2018-08-14 江瀚生物科技（上海）有限公司 一种用于改善男性精子质量的复合微生物制剂及其制备方法
CN105254745B (zh) * 2015-10-10 2019-01-25 姬生跃 一种生产猪源脂联素的方法
CN108277179B (zh) * 2018-03-07 2021-08-03 武汉生物样本库有限公司 一种枯草芽孢杆菌的高密度发酵及喷雾干燥方法
CN109549002A (zh) * 2018-12-29 2019-04-02 江苏澳华生物科技研究院有限公司 穿心莲药渣固态发酵生产猪用生物饲料方法及产品与应用
CN111481575A (zh) * 2020-04-24 2020-08-04 深圳市东荣生物科技有限责任公司 一种治疗二型糖尿病的复合微生物制剂及其制备工艺
JPWO2023007709A1 (fr) * 2021-07-30 2023-02-02
CN113881600A (zh) * 2021-10-29 2022-01-04 内蒙古自治区农牧业科学院 两种不同杆菌同时进行培养的液体培养基及其培养方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357360A (zh) * 2001-11-16 2002-07-10 郭飞融 生物降糖制剂
CN1875738A (zh) * 2005-06-06 2006-12-13 北京新纪元三色生态科技有限公司 一种饲料添加剂及其生产工艺和用途
CN101078003A (zh) * 2006-05-23 2007-11-28 上海创博生态工程有限公司 一种利用多菌种综合治理养殖水体制剂及制备方法
CN101703528A (zh) * 2009-11-25 2010-05-12 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61167622A (ja) * 1985-01-22 1986-07-29 Asahi Breweries Ltd 糖尿病コントロ−ル剤
JPH08205819A (ja) * 1995-02-03 1996-08-13 Kobayashi Kankyo Kagaku Kenkyusho:Kk 保健用飲食品
AU760878B2 (en) * 2000-02-17 2003-05-22 Biochem Industrial Co., Ltd. Purple photosynthetic bacteria and health foods
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
WO2005032568A1 (fr) * 2003-10-03 2005-04-14 Nihon Baio Kabushiki Kaisha Immunopotentialisateur, agent antiulcereux et aliments traites comprenant un produit a base de soja fermente et procede de production de produit a base de soja fermente
EP2030623A1 (fr) * 2007-08-17 2009-03-04 Nestec S.A. Prévention et/ou traitement de troubles métaboliques par la modulation de la quantité d'entérobactéries
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
ATE537707T1 (de) * 2008-05-16 2012-01-15 Nestec Sa Lactobacillus paracasei und gewichtskontrolle

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1357360A (zh) * 2001-11-16 2002-07-10 郭飞融 生物降糖制剂
CN1875738A (zh) * 2005-06-06 2006-12-13 北京新纪元三色生态科技有限公司 一种饲料添加剂及其生产工艺和用途
CN101078003A (zh) * 2006-05-23 2007-11-28 上海创博生态工程有限公司 一种利用多菌种综合治理养殖水体制剂及制备方法
CN101703528A (zh) * 2009-11-25 2010-05-12 王立平 一种治疗糖尿病的复合微生物制剂及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN MIN: "Microbial mixed culture fermentation and its applications", JOURNAL OF HANGZHOU NORMAL COLLEGE, no. 6, 30 November 1991 (1991-11-30), pages 88 - 94 *
See also references of EP2386624A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013133312A (ja) * 2011-12-27 2013-07-08 Tropical Plant Resources Institute Inc 非アルコール性脂肪性肝疾患および／または非アルコール性脂肪肝炎の治療薬
CN112772351A (zh) * 2021-01-15 2021-05-11 东北农业大学 一种马铃薯脱毒苗栽培基质及其制备方法
CN114276955A (zh) * 2021-12-15 2022-04-05 天津科技大学 一种固态发酵马铃薯薯渣生产蛋白饲料的微生物菌剂
CN114276955B (zh) * 2021-12-15 2024-03-08 天津北洋百川生物技术有限公司 一种固态发酵马铃薯薯渣生产蛋白饲料的微生物菌剂

Also Published As

Publication number Publication date
CN101703528A (zh) 2010-05-12
EP2386624A4 (fr) 2013-08-21
US20120093779A1 (en) 2012-04-19
JP5525622B2 (ja) 2014-06-18
JP2013512197A (ja) 2013-04-11
EP2386624B1 (fr) 2014-07-23
EP2386624A1 (fr) 2011-11-16
CN101703528B (zh) 2012-07-04

Similar Documents

Publication Publication Date Title
WO2011063597A1 (fr) Préparation microbienne complexe pour le traitement du diabète et son procédé de préparation et son utilisation
EP3858977B1 (fr) Souche pour la prévention et le traitement de maladies métaboliques et utilisation associée
CN111560331B (zh) 一株副干酪乳杆菌及其应用
CN106176833A (zh) 一种防治糖尿病并控制体重的复合益生菌液及其制备方法
CN106754619A (zh) 一种在谷物培养基中添加中药组分促进益生菌生长的方法
CN102973614B (zh) 一种防治老年痴呆症的益生菌活性保健液及其制备方法
CN107164295A (zh) 一种富硒微生物其制备方法及应用
CN111084385A (zh) 一种具有降血糖功效的益生菌制剂的功能性食品
CN113755377B (zh) 一种降解尿酸的副蕈状芽孢杆菌制剂及其制备方法与应用
CN115120646A (zh) 一种平衡肠道菌群的益生菌组合物及其制备方法和应用
CN100523170C (zh) 酪酸菌加嗜酸乳杆菌联合发酵工艺
CN106472932A (zh) 一种复合微生物饮品及其制备方法
CN113773978B (zh) 青春双歧杆菌及其应用
CN112831444A (zh) 鼠李糖乳杆菌lr2y及应用
JP3902015B2 (ja) 保健栄養食品の製造方法
US20230364166A1 (en) Application of postbiotics of inactivated lactobacillus casei iob-p9 in blood glucose reducing
CN115044507B (zh) 一种治疗和/或预防糖脂代谢异常的微生物组合物及其应用
CN1244686C (zh) 干酪乳杆菌lc2w菌株及其在制备抗高血压产品中的应用
CN111154694A (zh) 一种微生物发酵菌剂及其制备方法和应用
CN1579252A (zh) 复合酸饮料及其制备方法
CN1550545A (zh) 肠球菌属乳酸菌以及乳酸菌死菌体的制造方法
CN114540257B (zh) 一种卷曲乳杆菌iob901及其在降糖降脂方面的应用
CN116376770B (zh) 一种鼠李糖乳酪杆菌rh0121在制备降血糖制品中的应用
CN117603861A (zh) 一株格氏乳杆菌及其在缓解焦虑或改善睡眠中的应用
AU2023203324A1 (en) Optimized lactobacillus rhamnosus strain mp108 for enhancing cytokine regulating allergic immune response and method for obtaining the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10832504

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010832504

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012540257

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 13257368

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE